19/ Please visit https://t.co/JoGg6X0T9N for the full story and list of amazing contributors like @bega_murray @bvantine1 and many other twitter-less collaborators!
Children and AYAs with newly diagnosed soft tissue sarcomas who are receiving care at a @COGorg member site are now eligible to enroll in the CCDI Molecular Characterization Initiative. Find out more. https://t.co/SIN5edMcDr #Data4ChildhoodCancer
@theNCI@COGorg This is big news for pediatric patients with soft tissue sarcomas. Thanks to all at #CCDI and @COGorg who worked to get this open. Tell your friends and lets get this profiling done for all of our patients!
JUST ANNOUNCED: NCI's Childhood Cancer Data Initiative (#CCDI) launches the Molecular Characterization Initiative for #ChildhoodCancer research to foster data sharing through comprehensive cancer analysis. Learn more: https://t.co/mJqwRq2r1g #Data4ChildhoodCancer @NCIResearchCtr
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium https://t.co/oXFWqeMYkk Excited to report on the results of many years of work and which will impact therapy for patients with rhabdomyosarcoma.
We're making great progress on @theNCI’s Childhood #CancerData Initiative (CCDI).
An important part of the CCDI is the National #ChildhoodCancer Registry (NCCR), which uses 23 registries to identify and follow children and AYAs with cancer in the U.S.
https://t.co/GtMRvBGRu8
Hoping that this work will continue to move molecular and genetic profiling of pediatric tumors into the clinic to improve outcomes for our patients #childhoodcancer
Every single damn day there is another child like Francesca. A child who dies of cancer. A family who found out their child's cancer returned. A family that just learned their baby has cancer. We aren't doing enough. It makes me so angry we don't treat this like an emergency.
Upcoming phase III study of selumetinib in adult patients with NF1 and symptomatic inoperable plexiform neurofibromas #nfcon2021 @NCI_CCR_PedOnc @ChildrensTumor#RareDisease#NCIDTC @NCItreatment
Super excited to share this publication - a 7+ year journey of discovery, started when I was a post-doc and driven home by the exceptional Dr. Biniam Adane in the Stegmaier lab @DFBC_PedCare. Loss of STAG2 rewires Ewing Sarcoma transcriptional programs: https://t.co/GbQpN3k7Ra
We are excited to see this work published and hope it will help improve our understanding and clinical management of #RareCancers such as bone and soft-tissue #Sarcoma. Please get in touch if you are interested in collaborating with us!
Right now, @rtsundby is sharing his research on #neurofibromatosis at the 5th Annual Children's Cancer Foundation's Research Symposium. Local #pediatriccancer researchers will speak LIVE all day today - Join now: https://t.co/XunkZHUZ9O
Excited to share our new preprint identifying the immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. An effort lead by @neelamsinha05@Sanjusinha7 🧵 1/13 https://t.co/8aZQQ5g9Zw
What a great moment to see Senior Yeva Klingbeil at today’s girls track & field meet. Yeva’s teammates help her across the line in the 4X1 relay. Yeva continues her fight with cancer and we continue to be amazed by her spirit!! @CoachCloutier@ShenNews@Agostinoni_Ron
📣@danalynnecasey et al. found pediatric sarcomas with TP53 mutations to be associated with a radioresistant phenotype, highlighting the critical need for further investigation of novel therapeutic strategies - published today
https://t.co/VSHbcWNNxN
#Cancergenomics